Aktis Oncology, Inc. (AKTS)

Aktis Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Revenue	5.56	1.49	-
Gross Profit	5.56	1.49	-
Selling, General & Admin	-	12.58	8.88
Research & Development	-	40.95	25.92
Operating Expenses	-	53.54	34.79
Operating Income	-72.94	-52.05	-34.79
Interest Expense (Income)	-12.34	-8.1	-5.38
Other Expense (Income)	0.05	0.03	-0.78
Pretax Income	-60.65	-43.98	-28.64
Net Income	-60.65	-43.98	-28.64
Free Cash Flow	-69.34	11.9	-33.77
Gross Margin	100.00%	100.00%	-
Operating Margin	-1311.94%	-3500.34%	-
Profit Margin	-1090.81%	-2957.63%	-
Free Cash Flow Margin	-1247.19%	800.27%	-
EBITDA	-76.51	-54.59	-36.04
EBITDA Margin	-1375.99%	-3671.08%	-
Depreciation & Amortization	-3.52	-2.51	-2.03
EBIT	-72.99	-52.08	-34.02
EBIT Margin	-1312.77%	-3502.56%	-

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).